Jeff Johnson

Stock Analyst at Baird

(4.68)
# 178
Out of 5,149 analysts
154
Total ratings
60%
Success rate
29.26%
Average return

Stocks Rated by Jeff Johnson

Henry Schein
Feb 23, 2026
Upgrades: Outperform
Price Target: $78$100
Current: $80.21
Upside: +24.67%
Beta Bionics
Feb 18, 2026
Maintains: Neutral
Price Target: $28$14
Current: $11.57
Upside: +21.00%
Tandem Diabetes Care
Dec 16, 2025
Upgrades: Outperform
Price Target: $18$30
Current: $23.74
Upside: +26.37%
Zimmer Biomet Holdings
Dec 16, 2025
Downgrades: Neutral
Price Target: $117$100
Current: $97.97
Upside: +2.07%
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85$98
Current: $83.37
Upside: +17.55%
Alcon
Nov 13, 2025
Maintains: Outperform
Price Target: $95$98
Current: $83.08
Upside: +17.96%
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112$90
Current: $73.08
Upside: +23.15%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21$23
Current: $28.67
Upside: -19.78%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378$405
Current: $384.59
Upside: +5.31%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325$276
Current: $182.64
Upside: +51.12%
Upgrades: Outperform
Price Target: $180$238
Current: $241.84
Upside: -1.59%
Maintains: Outperform
Price Target: $67$70
Current: $25.29
Upside: +176.79%
Maintains: Outperform
Price Target: $53$61
Current: $13.60
Upside: +348.53%
Maintains: Outperform
Price Target: $78$67
Current: $13.30
Upside: +403.76%